SMMT slides nearly 15% as technical weakness follows FDA rejection on BLA

SMMT slides nearly 15% as technical weakness follows FDA rejection on BLA
Summit therapeutics slides 14.68% today

Summit Therapeutics Inc. (SMMT) dropped 14.68% today after the FDA issued a Complete Response Letter on its ivonescimab BLA, which delayed a key regulatory milestone for the company. The severity of the move is reinforced by sustained downside momentum, with SMMT trading below its 20-, 50-, and 200-day moving averages and prices pinned near intraday lows.

SMMT price prediction
24H 1.25%
$12.19
48H 0.91%
$12.15
7D -13.62%
$10.4
1M 10.3%
$13.28
3M 5.98%
$12.76
6M 14.45%
$13.78
12M 1.16%
$12.18
Current price: $12.04 -2.1000 14.86%
Real-time Data 12:57
Daily range 11.94 Arrow from to Icon 13.28
Weekly range 14.07 Arrow from to Icon 18.13
Loading...

Highlights

  • The FDA issued a Complete Response Letter for Summit Therapeutics' ivonescimab application in NSCLC, delaying potential U.S. approval.
  • Summit Therapeutics lost its first-mover advantage in the PD-1xVEGF bispecific antibody category and analyst price targets were adjusted after the FDA response.
  • Shares of Summit Therapeutics trade below key moving averages with persistent selling pressure and a projected five-day range of $10.03 to $14.27.

Analyst targets cut as FDA letter erodes SMMT’s drug lead

On November 15, 2026, the FDA issued a Complete Response Letter regarding Summit Therapeutics' Biologics License Application for ivonescimab in combination with platinum-based chemotherapy for previously treated NSCLC patients. This decision delayed potential U.S. approval and impacted Summit Therapeutics’ first-mover advantage in the PD-1xVEGF bispecific antibody drug class. No insider trading activity has been reported in recent months. Analyst price targets were adjusted following the FDA response.

Anton Kharitonov, expert at Traders Union, sees the FDA setback as a decisive blow to Summit Therapeutics’ momentum. Technical signals emphasize sustained selling with oversold oscillators offering little hope amid heavy pressure. He highlights that the stock’s failure to reclaim any key moving average and lack of bullish divergence point to weak sentiment among both traders and institutions. The absence of insider accumulation and price action stuck below $13.28 are further concerns. "Until the company regains regulatory momentum or volume shifts, the risk of new lows below $11.94 remains significant," he says.
Viktoras Karapetjanc, expert at Traders Union, remains constructive despite the FDA delay. He believes Summit Therapeutics retains industry relevance in the bispecific antibody segment, and sees volatility as a potential entry point. Karapetjanc notes that risk-reward improves as prices approach oversold levels, with strong support at $11.94. "I expect forward-looking investors to monitor for stabilization, as a rebound toward $13.28 could restore bullish structure in the coming sessions," he says.
Jainam Mehta, market strategist, views SMMT’s breakdown as technically significant but not necessarily terminal. He sees short-term exhaustion in selling, with volatility offering tactical setups for agile traders. Mehta suggests a tactical rebound could be in play if SMMT reclaims $13.28 on volume. "If sentiment diverges from price action, I would consider contrarian long entries with a tight stop below $11.94," he says.
Summit Therapeutics asset chart
Summit Therapeutics price dynamics. Source: TradingView.

Sustained downside and oversold signals mark technical landscape

SMMT is trading below its 20-day ($15.76), 50-day ($16.41), and 200-day ($16.15) moving averages, reflecting persistent pressure across all observed timeframes. The nearest resistance is at $13.28, while support is marked at today's low of $11.94. Momentum indicators point to weakness: the MACD signals selling pressure, ADX suggests a lack of strong trend, and RSI is neutral. Both the Stochastic RSI and CCI are in oversold zones, indicating potential selling exhaustion and the possibility of a rebound. Bull/Bear Power is negative, confirming sellers dominate intraday momentum. Price action is near session lows after opening with a downside gap, and volatility is elevated at 11.22%, underscoring negative momentum.

Earlier, analysts noted that Summit Therapeutics remained under technical pressure with a firmly negative outlook tied to regulatory developments and price declines. The latest FDA Complete Response Letter deepens this trend, and traders should monitor for stabilization or further breakdown as Summit's shares hover near critical support in a volatile environment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.